PMID: 9635538Jul 11, 1998Paper

Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma

Cancer
T S MokP Johnson

Abstract

Chemotherapy containing anthracycline is the standard initial treatment for aggressive non-Hodgkin's lymphoma (NHL), and the International Prognostic Index (IPI) is widely accepted as the standard tool for determining the prognosis of patients with this disease. However, the data on which the IPI was based primarily came from studies conducted in Western countries. It may not be directly applicable to Asian populations, in which the incidence of primary extranodal lymphoma (PENL) is known to be high. The authors conducted a retrospective study of 218 patients with aggressive NHL who were treated with chemotherapy. They analyzed the distribution of stage and pathology, prognostic factors, toxicity, and treatment outcome. The IPI was then applied and its ability to identify distinct prognostic groups tested. Eighty-six patients (39.4%) had lymph node lymphoma (LNL) and 132 (60.6%) had primary extranodal lymphoma (defined as non-Hodgkin's lymphoma with primary presentation, bulk of disease, and histologic confirmation at an extranodal site). The most common primary extranodal sites were the stomach (22%) and Waldeyer's tonsillar ring (18.9%). The complete response rate of PENL patients to chemotherapy containing anthracycline was ...Continue Reading

References

Sep 1, 1990·Hematological Oncology·R H LiangE K Chiu
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HoskinsJ M Connors
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F d'AmoreE Andersen
Aug 1, 1989·European Journal of Cancer & Clinical Oncology·R OtterR Willemze
Feb 1, 1989·British Journal of Cancer·R A CowanD Crowther
Apr 15, 1987·The American Journal of Cardiology·D LevyW P Castelli
Apr 1, 1985·European Journal of Cancer & Clinical Oncology·K AozasaA Sugimoto
Jul 1, 1968·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A BanfiE Salvini
Jan 1, 1972·Cancer·C FreemanS J Cutler
Jan 1, 1969·British Journal of Haematology·B ModanM Modan
Aug 15, 1984·International Journal of Cancer. Journal International Du Cancer·F C HoR K Khoo
May 1, 1995·Hematological Oncology·R LiangF C Ho
Dec 1, 1994·Leukemia & Lymphoma·M O MuenchM A Moore
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R LiangF C Ho
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project

❮ Previous
Next ❯

Citations

Jan 20, 2010·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Fabio M PaesAldo N Serafini
Jun 1, 2013·Medicina oral, patología oral y cirugía bucal·Janet-Ofelia Guevara-CanalesMaria-das-Graças-Afonso-Miranda Chaves
Oct 7, 2004·International Journal of Radiation Oncology, Biology, Physics·Takeshi NishiokaHiroki Shirato
Jun 23, 2009·The Korean Journal of Internal Medicine·Ock Bae KoCheolwon Suh
Sep 16, 2008·Clinical Oncology : a Journal of the Royal College of Radiologists·X WuC Yi
Dec 31, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ye-Xiong LiZi-Hao Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.